Structural Basis for the HLA-DR Association of Rheumatoid Arthritis

2000 ◽  
pp. 36-50 ◽  
Author(s):  
F. Sinigaglia ◽  
Z.A. Nagy
Keyword(s):  
Rheumatoid Arthritis ◽  
Structural Basis ◽  
Hla Dr

scholarly journals The effect of HLA–DR on susceptibility to rheumatoid arthritis is influenced by the associated lymphotoxin α–tumor necrosis factor haplotype

2003 ◽  
Vol 48 (1) ◽  
pp. 90-96 ◽  
Author(s):  
Julia Newton ◽  
Matthew A. Brown ◽  
Anita Milicic ◽  
Hans Ackerman ◽  
Chris Darke ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Hla Dr ◽  
Lymphotoxin Α ◽  
Necrosis Factor

scholarly journals Cytokines in chronic inflammatory arthritis. IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis.

1989 ◽  
Vol 170 (3) ◽  
pp. 865-875 ◽  
Author(s):  
J M Alvaro-Gracia ◽  
N J Zvaifler ◽  
G S Firestein
Keyword(s):  
Rheumatoid Arthritis ◽  
Class Ii ◽  
Tnf Alpha ◽  
Blood Monocytes ◽  
Ifn Gamma ◽  
Normal Peripheral Blood ◽  
Gm Csf ◽  
Hla Dr ◽  
Class Ii Mhc ◽  
Hla Dq

Granulocyte/macrophage CSF (GM-CSF) has recently been identified in rheumatoid arthritis (RA) synovial effusions. To study a potential role for GM-CSF and other cytokines on the induction of HLA-DR expression on monocytes and synovial macrophages, we analyzed the relative ability of recombinant human cytokines to induce the surface expression of class II MHC antigens on normal peripheral blood monocytes by FACS analysis. GM-CSF (800 U/ml) (mean fluorescence channel 2.54 +/- 0.33 times the control, p less than 0.001) and IFN-gamma (100 U/ml) (5.14 +/- 0.60, p less than 0.001) were the most potent inducers of HLA-DR. TNF-alpha and IL-4 also increased HLA-DR expression, although to a lesser degree [1.31 +/- 0.06 (p less than 0.02) and 1.20 +/- 0.03 (p less than 0.01), respectively]. IL-1 (40 U/ml), IL-2 (10 ng/ml), IL-3 (50 U/ml), IL-6 (100 U/ml), and CSF-1 (1,000 U/ml) did not affect surface HLA-DR density. GM-CSF also increased HLA-DR mRNA expression and surface HLA-DQ expression, but decreased CD14 (a monocyte/macrophage antigen) expression. The effect of GM-CSF on HLA-DR was not mediated by the generation of IFN-gamma in vitro because it was not blocked by anti-IFN-gamma mAb. GM-CSF was additive with IL-4 and low amounts (less than 3 U/ml) of IFN-gamma and synergistic with TNF-alpha. Because we have recently reported that supernatants of cultured RA synovial cells produce a non-IFN-gamma factor that induces HLA-DR on monocytes, we then attempted to neutralize this factor with specific anti-GM-CSF mAb. Four separate synovial tissue supernatants were studied, and the antibody neutralized the HLA-DR-inducing factor in each (p less than 0.01).

scholarly journals HLA-DR Expression of Synovium and Correlation with Clinical Features of Patients with Rheumatoid Arthritis

2000 ◽  
Vol 190 (3) ◽  
pp. 177-184 ◽  
Author(s):  
Hitoshi Kubota ◽  
Kyoji Okada ◽  
Kozo Sato ◽  
Masato Sageshima
Keyword(s):  
Rheumatoid Arthritis ◽  
Clinical Features ◽  
Hla Dr

scholarly journals Heat shock proteins, HLA-DR and rheumatoid arthritis

10.1038/3172 ◽  
1998 ◽  
Vol 4 (11) ◽  
pp. 1210-1210 ◽  
Author(s):  
Tina Rich ◽  
Ulrike Grüneberg ◽  
John Trowsdale
Keyword(s):  
Rheumatoid Arthritis ◽  
Heat Shock ◽  
Heat Shock Proteins ◽  
Hla Dr ◽  
Shock Proteins

scholarly journals The shared epitope revisited: shared epitope negative HLA-DR alleles influence susceptibility to rheumatoid arthritis

10.1186/ar272 ◽  
2001 ◽  
Vol 3 (S2) ◽  
Author(s):  
D Reviron ◽  
A Perdriger ◽  
E Toussirot ◽  
D Wendling ◽  
N Balandraud ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Shared Epitope ◽  
Hla Dr

The role of HLA-DR-DR and HLA-DR-DP interactions in genetic susceptibility to rheumatoid arthritis

1996 ◽  
Vol 46 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Aleth Perdriger ◽  
Pascal Guggenbuhl ◽  
Gerard Chalés ◽  
Philippe Le Dantec ◽  
Jacqueline Yaouanq ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Genetic Susceptibility ◽  
Hla Dr

Two faces of an illness: ankylosing spondylitis developed after rheumatoid arthritis

2009 ◽  
Vol 150 (43) ◽  
pp. 2000-2003
Author(s):  
Eszter Varga ◽  
Ágnes Petró ◽  
Rita Jáger ◽  
László Varga
Keyword(s):  
Rheumatoid Arthritis ◽  
Ankylosing Spondylitis ◽  
Hla B27 ◽  
Hla Dr ◽  
Spondylarthritis Ankylopoetica

A szerzők egy 35 éves nőbeteg kórtörténetét ismertetik, akinél 29 éves korában szeronegatív rheumatoid arthritist igazoltak a reumatológiai osztályon. A betegség remisszióját sikeres graviditás követte, majd két évvel később kizárólag axiális tüneteket mutató spondylarthritist diagnosztizáltak. A major hisztokompatibilitási komplex vizsgálata során a hagyományos szerológiai módszerekkel a HLA B27 spondylarthritis ankylopoeticára jellemző, valamint HLA DR1 rheumatoid arthritisre jellemző haplotípust mutattak ki. A HLA DRB-polimorfizmus vizsgálata során a rheumatoid arthritis létrejöttében és kórlefolyásában szerepet játszó HLA DR B1 0101 allél jelenlétét igazolták. A betegben tehát ritka kombinációként a spondylarthritis ankylopoetica és a rheumatoid arthritis létrejöttében is szerepet játszó HLA-formáció egyaránt megtalálható volt.

Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up

2019 ◽  
Vol 78 (5) ◽  
pp. 586-589 ◽  
Author(s):  
Pomme BM Poppelaars ◽  
Lilian H D van Tuyl ◽  
Maarten Boers
Keyword(s):  
Rheumatoid Arthritis ◽  
General Population ◽  
Cox Regression ◽  
Prospective Trial ◽  
Reference Sample ◽  
Health Assessment ◽  
Early Ra ◽  
Hla Dr ◽  
Mortality Ratio

ObjectivesMortality in patients with rheumatoid arthritis (RA) is higher than in the general population. We investigated mortality in the COBRA-trial cohort after 23 years follow-up, compared with a reference sample of the Dutch population.MethodsThe COBRA-trial randomised patients with early RA to sulfasalazine monotherapy (SSZ, n=79) or a combination of SSZ, low-dose methotrexate and initially high, step-down prednisolone (COBRA, n=76). We compared the mortality in the COBRA-trial up to 2017 to a reference sample of the general population in the Netherlands (standardised mortality ratio, SMR), and its relation to early prognostic factors through stepwise Cox regression.ResultsDuration of follow-up in patients alive was mean 23 (range 22–24) years. In total, 44 patients died (28%, SMR=0.80 [95% CI 0.59 to 1.06]); 20 of 75 COBRA patients (27%, SMR 0.75 [0.47 to 1.14]) and 24 of 79 SSZ patients (30%, SMR 0.85 [0.56 to 1.25]); p=0.61). In the reference sample of the general population, 55 people (36%) died. 5 factors were significantly associated with increased mortality hazard: damage progression at 28 weeks; high Health Assessment Questionnaire (HAQ) score and absence of HLA-DR 2 or 3; disease duration from start of complaints was also significant, but showed an uninterpretable pattern.ConclusionsThis prospective trial cohort study of early RA is one of the first to show similar mortality compared with the general population after 23 years of follow-up. It confirms that early, intensive treatment of RA has long-term benefits and suggests that treating to target is especially important for patients with poor prognosis.

Sign in / Sign up

Export Citation Format

Share Document